Brief: Cogent Biosciences Announces Phase 3 Peak Trial In Patients With Gastrointestinal Stromal Tumors Has Completed Enrollment
03/09/2024 13:45
Sept 3 (Reuters) - Cogent Biosciences Inc COGT.O :
* COGENT BIOSCIENCES ANNOUNCES PHASE 3 PEAK TRIAL IN
PATIENTS WITH
GASTROINTESTINAL STROMAL TUMORS (GIST) HAS COMPLETED ENROLLMENT
AND ADVANCED PAST INTERIM FUTILITY ANALYSIS
* COGENT BIOSCIENCES INC: TOP-LINE RESULTS EXPECTED BY END
OF 2025
* COGENT BIOSCIENCES INC: PEAK INTERIM FUTILITY ANALYSIS
COMPLETED
WITH NO CHANGES TO STUDY
Source text for Eikon: ID:nGNX9VF4f8
Further company coverage: COGT.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's